Published online November 1, 2006
PEDIATRICS Vol. 118 No. 5 November 2006, pp. e1328-e1335 (doi:10.1542/peds.2006-0359)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walsh, M. C.
Right arrow Articles by Ohlsson, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, M. C.
Right arrow Articles by Ohlsson, A.
Related Collections
Right arrow Premature & Newborn
Right arrowRelated AAP Red Book topics:
Yersinia enterocolitica and...
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Changes in the Use of Postnatal Steroids for Bronchopulmonary Dysplasia in 3 Large Neonatal Networks

Michele C. Walsh, MDa, Qing Yao, PhDa, Jeffrey D. Horbar, MDb,1, Joseph H. Carpenter, MSb,1, Shoo K. Lee, MBBS, FRCPC, PhDc and Arne Ohlsson, MDc

a Neonatal Research Network, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland
b Vermont Oxford Network, Burlington, Vermont
c Canadian Neonatal Network, Edmonton, Alberta, Canada

BACKGROUND. Postnatal corticosteroids were widely used in the 1990s in an attempt to reduce the incidence of bronchopulmonary dysplasia. However, high rates of short-term adverse effects and impaired neurodevelopmental outcomes were seen. In early 2002, a joint statement of the American Academy of Pediatrics and Canadian Paediatric Society called for limitation in the use of postnatal corticosteroids. The impact of this statement is not known.

OBJECTIVES. The purpose of this work was to determine the frequency of postnatal corticosteroid use and mortality and morbidities over time, particularly before and after the joint statement.

DESIGN/METHODS. We conducted a retrospective analysis of cohort data within 3 large network registries (the National Institute of Child Health and Development Neonatal Research Network [18 centers], the Vermont Oxford Network [444 centers], and the Canadian Neonatal Network [10 centers]) for the following 3 periods: prestatement (2001), statement (2002), and poststatement (2003) of very low birth-weight infants (501–1500 g). The National Institute of Child Health and Development Neonatal Research Network and the Vermont Oxford Network were also analyzed for longer-term trends from 1990 to 2003. Postnatal corticosteroid use, mortality at discharge, and neonatal morbidities (bronchopulmonary dysplasia at 36 weeks, late-onset infection >72 hours of age, necrotizing enterocolitis treated with surgery, and length of stay) between periods were compared.

RESULTS. Mean birth weight (range: 1022–1060 g), postmenstrual age (28 weeks), and gender (51% male) were similar between the networks. Race differed with more black infants in the National Institute of Child Health and Development Neonatal Research Network than the Vermont Oxford Network (38% vs 24%). Antenatal steroid use was similar (range: 61%–75%). Postnatal corticosteroid use rose from 1990 (8%–16%), peaked in 1996–1998 (24%–28%), and began to decline in 1999. Use in 2003 was significantly less than in 2001. Mortality and major morbidities were similar.

CONCLUSIONS. Postnatal corticosteroid use had decreased significantly in 3 large neonatal networks before the joint statement with further decreases after the statement with no apparent impact on mortality and short-term morbidity. Despite substantial decreases, ~8% of very low birth-weight infants continue to be treated with postnatal corticosteroid.

Key Words: bronchopulmonary dysplasia • corticosteroids

Abbreviations: PNS—postnatal steroid • BPD—bronchopulmonary dysplasia • VLBW—very low birth weight • NICHD NRN—National Institute of Child Health and Development Neonatal Research Network • VON—Vermont Oxford Network • CNN—Canadian Neonatal Network

Accepted Jun 8, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
E. C. Eichenwald and A. R. Stark
Management and Outcomes of Very Low Birth Weight
N. Engl. J. Med., April 17, 2008; 358(16): 1700 - 1711.
[Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
E. C Eichenwald and A. R Stark
Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia?
Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2007; 92(5): F334 - F337.
[Full Text] [PDF]